These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 36631624)

  • 1. Antibody-drug conjugates in lung cancer: dawn of a new era?
    Coleman N; Yap TA; Heymach JV; Meric-Bernstam F; Le X
    NPJ Precis Oncol; 2023 Jan; 7(1):5. PubMed ID: 36631624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
    Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
    Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
    Verma S; Breadner D; Raphael J
    Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
    Parisi C; Mahjoubi L; Gazzah A; Barlesi F
    Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
    Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
    Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
    Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs.
    Díaz-Rodríguez E; Gandullo-Sánchez L; Ocaña A; Pandiella A
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Drug Conjugates in Gynecologic Cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
    Sun T; Niu X; He Q; Liu M; Qiao S; Qi RQ
    Mol Clin Oncol; 2023 Jun; 18(6):47. PubMed ID: 37206431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
    Abuhelwa Z; Alloghbi A; Nagasaka M
    Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases.
    High P; Guernsey C; Subramanian S; Jacob J; Carmon KS
    Pharmaceutics; 2024 Jul; 16(7):. PubMed ID: 39065587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
    Jiang M; Li Q; Xu B
    Drug Resist Updat; 2024 Jul; 75():101086. PubMed ID: 38677200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads.
    Boni V; Sharma MR; Patnaik A
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-17. PubMed ID: 32315240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.
    Wang AJ; Gao Y; Shi YY; Dai MY; Cai HB
    Front Pharmacol; 2022; 13():1093666. PubMed ID: 36618922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer.
    Koukoutzeli C; Trapani D; Ascione L; Kotteas E; Marra A; Criscitiello C; Curigliano G
    Clin Med Insights Oncol; 2024; 18():11795549241260418. PubMed ID: 38894701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.
    Nguyen TD; Bordeau BM; Balthasar JP
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
    Reuss JE; Rosner S; Levy BP
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):217-226. PubMed ID: 38805313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.